Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 04/08/2024 at 23:01, 7 months 15 days ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants

Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE

published on 04/08/2024 at 23:01, 7 months 15 days ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 7 months 15 days ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE

published on 04/08/2024 at 23:00, 7 months 15 days ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030

Biophytis Étude Clinique BIO101 Obésité Perte Musculaire
BRIEF

published on 04/04/2024 at 23:05, 7 months 19 days ago

Biophytis annonce le succès de son Assemblée Générale du 2 avril 2024

Biophytis Biotechnologie Assemblée Générale Développement Clinique Maladies Liées À L'âge
BRIEF

published on 04/04/2024 at 23:05, 7 months 19 days ago

Biophytis Announces Unanimous Approval in General Meeting

Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE

published on 04/04/2024 at 23:00, 7 months 19 days ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30%

Shareholders Biophytis General Meeting Resolutions Approval
PRESS RELEASE

published on 04/04/2024 at 23:00, 7 months 19 days ago

RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
Biophytis annonce l'adoption de toutes les résolutions lors de son Assemblée Générale Mixte du 2 avril 2024. Les résultats sont disponibles sur leur site. Détails sur les activités et avertissement inclus

Biophytis Développement Biotechnologie Assemblée Générale Résultats
REGULATED PRESS RELEASE

published on 04/04/2024 at 23:00, 7 months 19 days ago

RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
Biophytis annonce l'approbation de toutes les résolutions présentées lors de son Assemblée Générale Mixte. Les détails des votes sont disponibles en ligne. En savoir plus sur BIOPHYTIS et ses candidats-médicaments

Biophytis Développement Assemblée Générale Resolutions Candidats-médicaments
REGULATED PRESS RELEASE

published on 04/04/2024 at 23:00, 7 months 19 days ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces approval of all resolutions at the Combined General Meeting held on April 2, 2024, with significant shareholder turnout. The Company specializes in therapeutics for age-related diseases

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases

Published on 11/22/2024 at 23:55, 1 day 2 hours ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 2 hours ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 3 hours ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day 3 hours ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 3 hours ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 7 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 8 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 8 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 9 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 10 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 1 day 8 hours ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 1 day 9 hours ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 1 day 11 hours ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 1 day 11 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 19 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News